ライフサイエンスコーパス: AFP

1 AFP can be regarded as a problem of the large-scale mult

2 AFP can still be used in the surveillance of HCC in Indo

3 AFP confirms the performance evidenced in other studies,

4 AFP level was evaluated against patient characteristics,

5 AFP responders at 1 mo had better overall survival than

6 AFP response, radiological response rate, and disease co

7 AFP was incubated in Ab1-coated wells; unbound AFP was t

8 AFPs have gained a large interest for their use in antif

9 nt (P < 0.001); KPS improvement (P < 0.001); AFP improvement (P < 0.001)] and reduction of therapeuti

10 onders, at 8.5 mo versus 4.8 mo (P = 0.018); AFP responders at 3 mo had overall survival of 13.3 mo,

11 .35 95% confidence interval (CI) 1.35-4.09], AFP >100 ng/mL (2.14 95% CI 1.17-3.93), and F4 fibrosis

12 R >/= 5 (P < 0.0001, hazard ratio, HR: 6.2), AFP > 200 (P < 0.0001, HR: 3.8), and Size >3 cm (P < 0.0

13 ies, Gunma, Japan) and AFP (IMMULITE(R) 2000 AFP, Siemens Healthcare Diagnostics, Tarrytown, New York

14 could be expanded to the TTV (</=115 cm(3) )/AFP (</=400 ng/mL) criteria in centers with at least 8-m

15 t (Maximum Mid-Expiratory Flow, MMEF25-75%), AFP and CEA for never smokers, light and never smokers w

16 tion of age, tumor site, and stage in > 94%, AFP in 12%, and YST in 27% of the replications.

17 limited value In diagnosing nvHCC, Having a AFP value over 400 ng/ml was associated with aggressive

18 Absolute AFP values did not correlate with SUV parameters (P = 0.

19 eptides, the assay can quantify low abundant AFP expression (0.5 ng) with good correlation with conve

20 n in the TCLT and in a model derived from an AFP-negative relapsing HB.

21 ater than 18 months (HR, 1.6; P = 0.043) and AFP greater than 400 at HCC diagnosis (HR, 3.0; P < 0.00

22 ain the autonomous regulation of albumin and AFP genes in the liver after birth.

23 ch as family history of lung cancer, CEA and AFP for light smokers, and lung function test (Maximum M

24 tion of two major cancer biomarkers (CEA and AFP) in different approaches.

25 the APRI score in diagnosis of cirrhosis and AFP in the diagnosis of HCC was determined using AUROC a

26 ents within the Metroticket 2.0 criteria and AFP model <=2 points exhibited heterogeneous recurrence

27 ilan criteria, Metroticket 2.0 criteria, and AFP model cut-off <=2 points (all P < 0.001) with c-stat

28 Both DCP and AFP were tested using enzyme immunoassay methods.

29 EXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL or lower at diagnosis.

30 ples were tested for both GPC3 by ELISA, and AFP by immunometric assay.

31 When combining triFc_AGP with INR and AFP, the panel had the greatest benefit in detection of

32 criteria, macroscopic vascular invasion, and AFP score>2 were independent predictors of recurrence, w

33 o-Biological Laboratories, Gunma, Japan) and AFP (IMMULITE(R) 2000 AFP, Siemens Healthcare Diagnostic

34 Initial AFP <400 ng/mL and AFP fall (initial minus pre-LDLT) >2000 ng/mL predicted

35 Cirrhosis, >1 nodule, and AFP >100 ng/mL were identified as preoperative predictor

36 Comparing the two groups, AUC for OPN and AFP were 0.51 (95 % CI: 0.39-0.63) and 0.79 (95 % CI: 0.

37 by baseline liver function, tumor size, and AFP level.

38 r staging, CPS, ECOG performance status, and AFP.

39 rence in tumor stage between ultrasound- and AFP-detected tumors (P = 0.53).

40 Such a combination of trehalose and AFPs also provides a novel approach for cold protection

41 e vacuum infiltration of Drimys angustifolia AFPs into the star fruit allowed an initial cryoprotecti

42 The capture anti-AFP (Ab1) was coated onto polystyrene well plates and bo

43 ts were used to label one member of the anti-AFP pair (Ab2) via amine-amine coupling using glutaralde

44 the proposed AuNP/TNW/AuNP coupled with anti-AFP through the analysis of the photocurrent change.

45 e 5 cm or smaller, solitary lesion, baseline AFP level lower than 100 ng/dL, and Eastern Cooperative

46 The midge and beetle AFPs are not homologous and their ice-binding sites are

47 we examine the molecular recognition between AFP and trehalose crystal interfaces using molecular dyn

48 43.8% were detected by ultrasound, 31.2% by AFP, and 25.0% by both surveillance tests.

49 Stratifying patients by AFP status in addition to radiological criteria may impr

50 enografts showed expression of beta-catenin, AFP, and Glypican-3 (GPC3).

51 Ontario Academic Health Sciences Centre AFP Innovation Fund and the Ontario Ministry of Health a

52 In contrast, AFP showed significant differences among different group

53 to further improve accuracy of conventional AFP-L3 tests.

54 ed device was successfully applied to detect AFP in human serum.

55 ction in AFP from > 1,000 ng/mL to different AFP thresholds before LT on survival and HCC recurrence

56 ut nonmetastatic, HCC and initially elevated AFP, possibly enabling early therapy monitoring independ

57 measured in expression of PAPPA, FLT1, ENG, AFP, PGF, and LGALS14, but not LGALS13 or the lineage ma

58 the high-resolution structure of the entire AFP particle in the extended state, trace 11 protein cha

59 et that is classified by an extreme EpCAM(+) AFP(+) gene expression signature and associated with poo

60 serve as a key molecular target for EpCAM(+) AFP(+) HCC subtype.

61 coprotein specifically activated in EpCAM(+) AFP(+) HCC.

62 erum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of 200 Egyptian CHC pat

63 Median alpha fetoprotein (AFP) at diagnosis and pre-LDLT were 78.1 ng/mL (3-58 200

64 rs, and 8 years or older; alpha fetoprotein (AFP) concentration of 100 ng/mL or lower and 101-1000 ng

65 er of 3 to 5 cm and serum alpha fetoprotein (AFP) greater than 100 ng/mL at transplant yielded a 50%

66 et ratio index (APRI) and alpha fetoprotein (AFP) in Ghana.

67 rveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm, downstream harms fr

68 antigen (CEA), bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) were identified and i

69 High alpha-fetoprotein (AFP) > 1,000 ng/mL is associated with poor outcomes afte

70 Elevated alpha-fetoprotein (AFP) >/= 10,000 ng/mL was associated with worse outcome,

71 3.1; P = 0.005) and with alpha-fetoprotein (AFP) >= 100 ng/mL at LT (HR, 2.4; P = 0.009).

72 ikingly, patients with an alpha-fetoprotein (AFP) >=10 ng/mL and having used sirolimus for >=3 months

73 ltivariate analysis, only alpha-fetoprotein (AFP) >=200 ng/mL (P = 0.006) and large tumor size (P = 0

74 ents with a high level of alpha-fetoprotein (AFP) (>100 ng/dL) was conducted.

75 serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropin (hCG) 151,1

76 sed two model biomarkers [alpha-fetoprotein (AFP) and cancer antigen 125 (CA125)] to demonstrate the

77 hrough the examination of alpha-fetoprotein (AFP) and ultrasound for patients at risk in developing H

78 or etiology of cirrhosis, alpha-fetoprotein (AFP) at liver transplant, tumor diameter, tumor patholog

79 REAT), which incorporates alpha-fetoprotein (AFP) at liver transplantation (LT), microvascular invasi

80 ymphocyte ratio (NLR) and alpha-fetoprotein (AFP) have been associated with recurrence risk.

81 ild-Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual survival.

82 nsitive and specific than Alpha-fetoprotein (AFP) in the diagnosis of HCC among the White population.

83 Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC).

84 Serum alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinomas (HCCs)

85 Alpha-fetoprotein (AFP) is often expressed at high levels in HCC and is an

86 tial necrosis, high serum alpha-fetoprotein (AFP) level (>100 ng/mL), and Barcelona Clinic Liver Canc

87 atients (542 men), median alpha-fetoprotein (AFP) level at the time of LT was 8.3 ng/mL; 9.4% had mic

88 em, tumor size, and serum alpha-fetoprotein (AFP) level were investigated using Cox proportional haza

89 stases and a rising serum alpha-fetoprotein (AFP) level.

90 losed a slightly elevated alpha-fetoprotein (AFP) of 12.3 ug/L (upper limit of normal, 8.0 ug/L), and

91 Alpha-fetoprotein (AFP) represents a classical model system to study develo

92 developed to detect human alpha-fetoprotein (AFP) using carbon dots (C-Dots).

93 The AUC value for alpha-fetoprotein (AFP) was 0.80 (0.74-0.87) compared to 0.94 (0.9-0.97) fo

94 under optimal conditions, alpha-fetoprotein (AFP) was detected at a limit of detection of 1ngmL(-1) a

95 Levels of human alpha-fetoprotein (AFP) were monitored in the serum of animals.

96 rface antigen (HBsAg) and alpha-fetoprotein (AFP) with the lowest concentration of naked-eye detectio

97 As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HC

98 ciated gene expression of alpha-fetoprotein (AFP), Albumin (Alb), Glucose-6-phosphatase (G6Pc), SRY (

99 ntigen 19-9 (CA 19-9) and alpha-fetoprotein (AFP), commonly used to help in the diagnosis of iCCA and

100 onal serum marker for HB, alpha-fetoprotein (AFP), has its limitations.

101 with elevated circulating alpha-fetoprotein (AFP), low rate of necrosis/fibrosis after treatment, and

102 was associated with serum alpha-fetoprotein (AFP), tumor-node-metastasis (TNM) stage, and lymph node

103 or trace level sensing of alpha-fetoprotein (AFP), which is a well know cancer biomarker.

104 umour burden score (TBS), alpha-fetoprotein (AFP), year of transplantation, underlying cause of cirrh

105 trasensitive detection of alpha-fetoprotein (AFP).

106 ription factor SOX-17 and alpha-fetoprotein (AFP).

107 anel [APOH, ORM2, C3, and alpha-fetoprotein (AFP)] has proven to outperform AFP, the known HCC serum

108 lume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP; </=400 ng/mL) score.

109 as patients with negative alpha-fetoprotein (AFP; n = 1), resulting in 24 patients and 57 scans that

110 internal clathrate water network of the fish AFP Maxi, which extends to the protein's outer surface,

111 ZBTB20 was dispensable for AFP silencing in other tissues outside liver.

112 new national policy has been implemented for AFP > 1,000 ng/mL requiring a decrease to < 500 ng/mL be

113 cluded in the immunosensor modification (for AFP: 1st and 3rd approaches: 1.36fg/ml in comparison wit

114 we report a previously unidentified role for AFPs in effectively inhibiting trehalose precipitation i

115 This newly uncovered role for AFPs may help explain the long-speculated role of AFPs i

116 ccording to Metroticket 2.0 model and French AFP model with Milan criteria serving as benchmark.

117 the spruce budworm Choristoneura fumiferana AFP, including stereo-specific binding and consequential

118 In down-staging groups, AFP >= 100 (HR, 2.6; P = 0.02) was the only independent

119 .001) and late stage tumours (P < 0.001) had AFP over 400 ng/ml.

120 Of the 665 LT recipients, 457 (68.7%) had AFP-producing tumors, and 208 (31.3%) had non-AFP-produc

121 January 2005 and September 2015 and who had AFP > 1,000 ng/mL at least once before LT.

122 Having AFP below 400 ng/ml was associated with longer survival

123 nadensis, and demonstrate that the hemolymph AFPs are crucial for inhibiting trehalose crystallizatio

124 Of 123 patients with a high AFP level (>100 ng/dL), 12 patients achieved restored no

125 .001) and non-surgical candidates had higher AFP levels.

126 His AFP level declined rapidly after resection, and computed

127 His AFP normalized after surgery.

128 However, 2 weeks later, his AFP level rose again, and repeat MRI of the brain showed

129 tion of in silico models for Maxi and type I AFP binding to sII hydrates.

130 etween fluorescence and clinically important AFP concentrations (range: 0-350 ng/mL with a correlatio

131 8% versus 67.0% for those with a decrease in AFP to 101-499 ng/mL (P < 0.001) and 88.4% for those wit

132 Low initial AFP level, a significant drop in AFP with DS and low tumor grade, favorably influence sur

133 n the proposed method and an ELISA method in AFP and CA125 measurements of serum samples were less th

134 ed to evaluate the effects of a reduction in AFP from > 1,000 ng/mL to different AFP thresholds befor

135 stricting LT to patients with a reduction in AFP from > 1,000 to < 500 ng/mL, validating the recently

136 ntally regulated and plays a central role in AFP postnatal repression.

137 Our data define a cognate ZBTB20 site in AFP promoter which mediates the postnatal repression of

138 Increased AFP levels correlated with tumor growth.

139 Initial AFP <400 ng/mL and AFP fall (initial minus pre-LDLT) >20

140 Low initial AFP level, a significant drop in AFP with DS and low tum

141 with HCC recurrence: microvascular invasion, AFP at time of LT, and the sum of the largest viable tum

142 The last AFP measurement before LT was > 1,000 ng/mL in 72.0%, de

143 ly recurrence of HBV-HCC, especially for low-AFP patients.

144 %) had non-AFP-producing tumors (the maximum AFP level before an LT was </=10 ng/mL).

145 ded age, sex, liver disease diagnosis, MELD, AFP, NLR, radiographic Milan status, and number of LRT t

146 The midge AFP is expressed as a family of isoforms at low levels i

147 The detection limits (0.06pg/mL AFP and 0.001U/mL CA125) and linear ranges (0.2pg/mL-0.6

148 CA125) and linear ranges (0.2pg/mL-0.68ng/mL AFP and 0.003-25U/mL CA125) of this method are the same

149 d serve as a potential marker for monitoring AFP-negative HCC patients.

150 d a ZBTB20-binding site at -104/-86 of mouse AFP gene, flanked by two HNF1 sites and two C/EBP sites

151 ot produce AFP (hereafter referred to as non-AFP-producing tumors), and to identify factors influenci

152 FP-producing tumors, and 208 (31.3%) had non-AFP-producing tumors (the maximum AFP level before an LT

153 with radiographically apparent HCC have non-AFP-producing tumors that have more favorable pathologic

154 Patients with non-AFP-producing tumors also had significantly superior rec

155 Patients with non-AFP-producing tumors had radiographic tumor characterist

156 ictors of recurrence among patients with non-AFP-producing tumors include radiologic (>2 tumors [HR,

157 nsplant HCC recurrence for patients with non-AFP-producing tumors is predicted by important radiologi

158 d recurrence lowest, among patients with non-AFP-producing tumors within the Milan criteria (71% surv

159 uencing recurrence in LT recipients with non-AFP-producing tumors.

160 0 criteria (0.014, Z = 0.023; P = 0.509) nor AFP model (-0.014, Z = -0.021; P = 0.492) provided signi

161 41.2% (n = 160) Of patients had normal AFP level.

162 ng/dL), 12 patients achieved restored normal AFP levels (<13 ng/dL) and exhibited median overall surv

163 In addition to 12 novel AFP glycoforms, our quantification result uncovers five

164 This novel AFP photoelectric immunosensor exhibited sensitive detec

165 r was successfully exploited for analysis of AFP in real human blood plasma, serum and urine sample.

166 AUC of AFP was 0.88 (95% CI 0.81-0.94) in diagnosis of HCC.

167 In Sokoto State, 58 cases of AFP were found from a search of 9426 households.

168 n isolates reflects effective combination of AFP and environmental surveillance in Pakistan.

169 n isolates reflects effective combination of AFP and ES surveillance working in Pakistan.

170 sitively correlated to the concentrations of AFP antigen.

171 rm maintenance in resource-poor countries of AFP surveillance as a platform for surveillance of vacci

172 The molecular details of AFP adsorption-inhibition is uncertain but is proposed t

173 mmunosensor exhibited sensitive detection of AFP with an ultrahigh sensitivity of 0.001 ng mL(-1) and

174 Moreover, the practical determination of AFP in human serum is also investigated, demonstrating i

175 Therefore, the effectiveness of AFP in the surveillance of HCC patients and identifying

176 nted polymer was also used for estimation of AFP in the concentration range of 3.96-80.0 ng mL(-1), w

177 Expression of AFP in nonmalignant liver can occur, particularly in a s

178 We verified expression of AFP in normal and diseased tissue and generated an affin

179 Expression of AFP was investigated using database searches, by qPCR, a

180 ameters most associated with the increase of AFP >= 10 ng/ml in Indonesia should be evaluated.

181 ameters most associated with the increase of AFP >=10 ng/ml according to multivariate analysis were t

182 , consistent with a more direct mechanism of AFP-mediated repression of gene expression.

183 ated more than a decade ago that mixtures of AFP isoforms can exhibit synergistic enhancement of each

184 model may be limited by the small number of AFP cases in some districts.

185 onstrated that transcriptional repression of AFP gene by ZBTB20 was liver-specific.

186 r which mediates the postnatal repression of AFP gene in the liver.

187 BTB20 in vitro, as well as the repression of AFP promoter activity by ZBTB20.

188 quence-specific transcriptional repressor of AFP.

189 systems while revealing the specificities of AFP.

190 The sensitivity and specificity of AFP in the surveillance of HCC in Indonesia with a cut-o

191 imilarly, the sensitivity and specificity of AFP were 62.9% and 93.3% at an ROC - derived optimum cut

192 Stool specimens of AFP patients and sewage samples collected from 60 active

193 health facilities) is a critical strategy of AFP surveillance systems for highly sensitive and timely

194 o vaccine introduction, and strengthening of AFP surveillance) that have contributed to the interrupt

195 ng Nigerian patients was higher than that of AFP for large tumours with diameter >/=3 cm.

196 99 and was significantly larger than that of AFP which was 0.85 (p < 0.001).

197 s were all significantly lower than those of AFP.

198 en some controversies regarding the usage of AFP concerning its low sensitivity and specificity in de

199 ose also enhances the antifreeze activity of AFPs.

200 otection, indicating that the application of AFPs can increase the quality of frozen star fruit.

201 ition (IRI) activity of all major classes of AFPs using cryoscopy, sonocrystallization, and recrystal

202 rowth inhibition by the different classes of AFPs: blocking fast ice growth requires rapid nonbasal p

203 may help explain the long-speculated role of AFPs in freeze-tolerant species.

204 Additional refinements based on AFP and wait time may further improve post-LT outcomes i

205 ut there is a paucity of data on the optimal AFP threshold before LT.

206 thin Metroticket 2.0 criteria (P = 0.021) or AFP model <=2 points (P = 0.014).

207 than 10% regardless of largest tumor size or AFP.

208 -fetoprotein (AFP)] has proven to outperform AFP, the known HCC serum biomarker, alone, in this study

209 reporting non-polio acute flaccid paralysis (AFP) (OR = 1.13, 95% CI 1.02-1.26 for a 1-unit increase

210 ns of patients with acute flaccid paralysis (AFP) and sewage samples collected from 60 environmental

211 Surveillance for acute flaccid paralysis (AFP) is a fundamental cornerstone of the global polio er

212 fied with non-polio acute flaccid paralysis (AFP) reported through polio surveillance, information on

213 ors associated with acute flaccid paralysis (AFP) surveillance, routine immunization, and polio suppl

214 that can complement acute flaccid paralysis (AFP) surveillance.

215 as limited by the small numbers of non-polio AFP cases in some districts, which was reflected by larg

216 1.02-1.26 for a 1-unit increase in non-polio AFP per 100,000 persons aged <15 years).

217 Automated function prediction (AFP) of proteins is of great significance in biology.

218 te that the new fungal protease preparations AFP and FPII, bacterial protease preparation HT and the

219 fungal and bacterial protease preparations (AFP, FPII, F60K and HT) was evaluated over a range of pH

220 ng tumors or with tumors that do not produce AFP (hereafter referred to as non-AFP-producing tumors),

221 s for patients with HCCs that do not produce AFP are limited.

222 re, we characterize the antifeeding prophage AFP from Serratia entomophila by cryo-electron microscop

223 solates (HPIs) were hydrolysed by proteases (AFP, HT, ProG, actinidin and zingibain).

224 peptides inspired by the antifreeze protein (AFP) and antifreeze glycoprotein (AFGP) are attached ont

225 An antifreeze protein (AFP) with no known homologs has been identified in Lake

226 se duration, toxicities, alpha-feto protein (AFP) response, and radiological response.

227 hile insect hyperactive antifreeze proteins (AFP) are soluble and generally small.

228 Since antifreeze proteins (AFPs) act as KHIs, we have used their solved x-ray cryst

229 Antifreeze proteins (AFPs) are a unique class of proteins that bind to growin

230 Antifreeze proteins (AFPs) have the ability to modify ice crystal growth and

231 Antifreeze proteins (AFPs) protect certain cold-adapted organisms from freezi

232 Antifreeze proteins (AFPs), known to protect organisms from freezing by lower

233 tective capabilities of antifreeze proteins (AFPs), we hypothesized that supplementation of islets wi

234 Several ABI5/ABF binding proteins (AFPs) inhibit ABA response, resulting in extreme ABA res

235 Overexpression of ABI5/ABF binding proteins (AFPs) results in extreme ABA resistance of seeds via mul

236 Overexpression of ABI5/ABF binding proteins (AFPs) results in extreme ABA resistance of seeds via mul

237 The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear.

238 TCR that recognizes the HLA-A*02-restricted AFP(158-166) peptide, FMNKFIYEI, with an optimum balance

239 ermore, we present the first study revealing AFP glycopeptide signatures of individual HCC patients,

240 he lungs and mediastinal nodes with a rising AFP level starting in January 2011.

241 r improve the performance of the large-scale AFP by incorporating massive protein-protein network inf

242 l for End-stage Liver Disease (MELD) scores, AFP levels, and neutrophil-lymphocyte ratios (NLR); were

243 comorbidities, Child-Pugh score, BCLC, serum AFP level, and (90)Y global administered activity.

244 s were less likely to exhibit elevated serum AFP (p < 0.0001).

245 erval [CI] = 8.9, 114; P < .001), high serum AFP level (odds ratio = 4.4; 95% CI = 1.3, 16; P = .02),

246 His serum AFP level was elevated at 47 ng/mL.

247 group, the BCLC staging system and the serum AFP level were associated with PFS (P = 0.04) and OS (P

248 In the multivariate analysis, tumor size, AFP < 100 ng/mL and serum alkaline phosphatase were inde

249 Additional interactions between some AFPs and histone deacetylase subunits were observed in y

250 , Eastern Cooperative Oncology Group status, AFP level, and PVT extent.

251 tylase activity by trichostatin A suppressed AFP effects on a small fraction of the ABI5-regulated ge

252 The synthesized AFP-imprinted polymer possesses excellent selectivity to

253 hat supplementation of islets with synthetic AFP analog antiaging glycopeptide (AAGP) would enhance p

254 r proportion of ultrasound-related harm than AFP-related harm (22.8% vs. 11.4%; P < 0.001).

255 tests-more often related to ultrasound than AFP.

256 ancer-specific overexpression indicates that AFP may be a promising target for immunotherapy.

257 As a proof of concept, the AFP antigen can be quantitatively detected by the propos

258 In multivariable analysis, a decrease in the AFP to 101-499 ng/mL was associated with a > 2-fold redu

259 Furthermore, we provide the structure of the AFP sheath-baseplate complex in a contracted state.

260 and shows preferential strong binding of the AFP to the fast growing surfaces of the sugar crystal.

261 ed to form a sandwich immunocomplex with the AFP bound to the Ab1-coated wells.

262 Z (NINJA) protein, it was suggested that the AFPs interact with the co-repressor TOPLESS to inhibit A

263 Collectively, these results suggest that the AFPs participate in multiple mechanisms modulating ABA r

264 This study shows that the AFPs that inhibit ABA response have intrinsic repressor

265 ariables: age, type of locoregional therapy, AFP, donor sex, body mass index, or nonalcoholic steatoh

266 Cs and 0.818 for early NASH HCCs compared to AFP alone (0.761 and 0.641, respectively).

267 ecause of the extensive resources devoted to AFP surveillance, multiple opportunities exist for addit

268 We concluded that GPC3 is inferior to AFP as a serum marker for HB.

269 ed T-cell receptor (TCR) with specificity to AFP/HLA-A*02(+) tumors.

270 Pre treatment AFP has a limited value In diagnosing nvHCC, Having a AF

271 The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear.

272 er for patients beyond Milan, but within TTV/AFP (16 of 38; 42.1%), than for those within Milan (49 o

273 in Milan and 38 beyond Milan, but within TTV/AFP.

274 criteria, and 32 beyond Milan but within TTV/AFP.

275 red to patients beyond Milan, but within TTV/AFP.

276 P was incubated in Ab1-coated wells; unbound AFP was then washed away with Tween-20.

277 as associated with lower odds of undertaking AFP.

278 s salts and alcohols, the advantage of using AFPs as an additive is that they do not alter the physic

279 h data on process indicators associated with AFP surveillance and routine immunization, showing stati

280 n in HCC recurrence (P = 0.02) compared with AFP > 1,000 ng/mL at LT.

281 h radiographically apparent HCC lesions with AFP-producing tumors or with tumors that do not produce

282 hin Metroticket 2.0 criteria (75.3%) or with AFP model <=2 points (74.1%) was inferior to that observ

283 was not performed in 45.4% of patients with AFP > 1,000 ng/mL at LT versus 12.8% of those with AFP o

284 ility at 5 years was 35.0% for patients with AFP > 1,000 ng/mL versus 13.3% for patients with AFP of

285 Patients with AFP >400 ng/mL were excluded, and, as such, the Milan gr

286 In the subgroup of patients with AFP <200 ng/mL, high MTA1dE4, but not total MTA1, expres

287 p was modified to include only patients with AFP <400 ng/mL; these patients were compared to patients

288 of 101-499 ng/mL and 7.2% for patients with AFP <= 100 ng/mL at LT (P < 0.001).

289 > 1,000 ng/mL versus 13.3% for patients with AFP of 101-499 ng/mL and 7.2% for patients with AFP <= 1

290 the second-line setting among patients with AFP>=400 ng/dL.

291 s in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating partic

292 e, and recurrence highest, for patients with AFP-producing tumors outside the Milan criteria (40% sur

293 cteristics similar to those of patients with AFP-producing tumors, but, pathologically, they had fewe

294 uperior survival compared with patients with AFP-producing tumors.

295 s (8.8% vs 22%; P < .001) than patients with AFP-producing tumors.

296 Meier 5-year post-LT survival for those with AFP > 1,000 ng/mL at LT was 48.8% versus 67.0% for those

297 9 ng/mL (P < 0.001) and 88.4% for those with AFP <= 100 ng/mL at LT (P < 0.001).

298 AFP of 101-499 ng/mL and 10.3% of those with AFP <= 100 ng/mL at LT (P < 0.001).

299 1,000 ng/mL at LT versus 12.8% of those with AFP of 101-499 ng/mL and 10.3% of those with AFP <= 100

300 tar fruits that were vacuum infiltrated with AFPs retained their drip loss constant after 15 days.